TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07710664: An Exploratory Clinical Study of NWRD09 in Participants With Persistent HPV16 Infection in the Anal Region: Safety and Preliminary Efficacy Observation

Sponsor: Newish Biotech (Wuxi) Co., Ltd. · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,938,824

Rescue Site Savings

+$1,939,224

Unlock Full NCT07710664 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07710664 Rescue Dossier →